Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Multiple Oral Doses of BI 425809 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period, One-sequence Trial)

NCT05258110 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05258110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Multiple Oral Doses of BI 425809 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period, One-sequence Trial)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2022
Completion date
May 31, 2022
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy